AR107010A1 - Derivados de piperidina puenteados - Google Patents

Derivados de piperidina puenteados

Info

Publication number
AR107010A1
AR107010A1 ARP160103753A ARP160103753A AR107010A1 AR 107010 A1 AR107010 A1 AR 107010A1 AR P160103753 A ARP160103753 A AR P160103753A AR P160103753 A ARP160103753 A AR P160103753A AR 107010 A1 AR107010 A1 AR 107010A1
Authority
AR
Argentina
Prior art keywords
halogen
lower alkyl
alkyl substituted
substituted
hydrogen
Prior art date
Application number
ARP160103753A
Other languages
English (en)
Inventor
Ratni Hasane
Limberg Anja
Jaeschke Georg
Baumann Karlheinz
Maria Rodriguez Sarmiento Rosa
Neidhart Werner
Jakob-Roetne Roland
Galley Guido
Bartels Bjoern
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR107010A1 publication Critical patent/AR107010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Alzheimer, la angiopatía amiloide cerebral, la hemorragia cerebral hereditaria con amiloidosis de tipo holandés (HCHWA-D), la demencia multiinfarto, la demencia pugilística o el síndrome de Down. Reivindicación 1: Compuesto de fórmula (1), en las que: HetAr es un grupo heterarilo de cinco o seis elementos, que contiene uno, dos o tres heteroátomos seleccionados de entre N, O ó S; R¹ es hidrógeno, alquilo inferior, alquilo inferior sustituido con halógeno, halógeno o alcoxi inferior; R² es alquilo inferior sustituido con halógeno, -CH₂-cicloalquilo C₃₋₆ sustituido con uno o dos sustituyentes seleccionados de entre alquilo inferior sustituido con halógeno o halógeno, o es alquenilo inferior sustituido con halógeno; R³ es hidrógeno, alquilo inferior sustituido con halógeno, alquilo inferior, halógeno, cicloalquilo C₃₋₆ o alquilo inferior sustituido con hidroxi; n es 1 ó 2; para n = 2, R¹ puede ser independiente; Y es CH o N; o una sal de adición de ácido farmacéuticamente aceptable de los mismos, una mezcla racémica o el enantiómero y/o isómero óptico y/o estereoisómero de los mismos correspondiente.
ARP160103753A 2015-12-10 2016-12-07 Derivados de piperidina puenteados AR107010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15199260 2015-12-10

Publications (1)

Publication Number Publication Date
AR107010A1 true AR107010A1 (es) 2018-03-14

Family

ID=54848457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103753A AR107010A1 (es) 2015-12-10 2016-12-07 Derivados de piperidina puenteados

Country Status (7)

Country Link
US (2) US10562903B2 (es)
EP (1) EP3386978B1 (es)
JP (1) JP6872550B2 (es)
CN (1) CN108137579B (es)
AR (1) AR107010A1 (es)
TW (1) TWI629278B (es)
WO (1) WO2017097728A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
WO2018001918A1 (en) * 2016-06-27 2018-01-04 F. Hoffmann-La Roche Ag Triazolopyridines as gamma-secretase modulators
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
AR110001A1 (es) * 2016-11-01 2019-02-13 Hoffmann La Roche Derivados heteroarilo bicíclicos
AU2018247765B2 (en) 2017-04-03 2023-11-23 F. Hoffmann-La Roche Ag Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
WO2019191092A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
MX2020014098A (es) 2018-06-27 2021-05-27 Ptc Therapeutics Inc Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
KR20210054515A (ko) 2018-09-03 2021-05-13 에프. 호프만-라 로슈 아게 바이사이클릭 헤테로아릴 유도체
AU2019395774A1 (en) * 2018-12-13 2021-04-08 F. Hoffmann-La Roche Ag 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of Alzheimer's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
WO2005061513A1 (en) 2003-12-24 2005-07-07 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
JP4871290B2 (ja) * 2005-10-06 2012-02-08 日本曹達株式会社 架橋環状アミン化合物および有害生物防除剤
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019326A1 (en) 2008-08-14 2010-02-18 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
BR112014018027B1 (pt) 2012-01-26 2020-10-27 Ptc Therapeutics, Inc composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
US9586955B2 (en) 2012-02-10 2017-03-07 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP2872493B1 (en) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy
JP2016518421A (ja) 2013-05-14 2016-06-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール
WO2014209841A2 (en) 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
NZ725008A (en) 2014-05-15 2019-11-29 Hoffmann La Roche Compounds for treating spinal muscular atrophy
WO2017080967A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
WO2017097728A1 (en) 2017-06-15
CN108137579A (zh) 2018-06-08
CN108137579B (zh) 2022-01-07
TWI629278B (zh) 2018-07-11
JP6872550B2 (ja) 2021-05-19
EP3386978A1 (en) 2018-10-17
EP3386978B1 (en) 2021-01-27
US20200291034A1 (en) 2020-09-17
TW201725209A (zh) 2017-07-16
US20190010156A1 (en) 2019-01-10
JP2018536671A (ja) 2018-12-13
US10562903B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
AR107010A1 (es) Derivados de piperidina puenteados
AR105965A1 (es) Derivados de piperidina puenteados
AR110122A1 (es) Fenoxitriazoles
AR109829A1 (es) Derivados de piperidina puenteados
AR110001A1 (es) Derivados heteroarilo bicíclicos
CR20180022A (es) Derivados etinilo.
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
ECSP13012858A (es) Derivados de piperidina puenteada
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR070398A1 (es) Derivados sustituidos de indol
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR087752A1 (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
AR074304A1 (es) Moduladores heterociclicos de gamma- secretasa
AR094225A1 (es) Peptidos como agonistas de oxitocina
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP14013296A (es) Derivados de etinilo
AR070188A1 (es) Derivados de sulfonamidas sustituidas
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
EA201692488A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
AR097721A1 (es) Derivados de etinilo
AR099047A1 (es) Derivados etinilo
AR114374A1 (es) Compuestos herbicidas